Characteristics of an Effective Mammalian Cell Line Generation Process for Bio-Pharmaceutical Production
Quickly and consistently generating stable, high productivity cell lines that produce protein of outstanding quality are the goals of any mammalian cell line process.
This talk will explore how steps in the generation of mammalian cell lines were optimized to make a process more efficient and outline certain risks that were taken to improve timelines and throughput.
Data collected from the development of over 200 cell lines, each producing a different antibody or recombinant protein will be summarized. An outline of our current CHO cell line development process that consistently yields clonal lines and upstream culture conditions that result in 2.5 – 5.0 g/L antibody production in five to six months will be presented.
Discussed topics will include:
- Optimizing the Gene Construct
- Minimizing Resources and Time During Clonal Selection
- Balancing Titer and Stability vs. Speed
- Addressing Protein Quality and Other Characteristics During the Process
- Finding a Quick Upstream Development Process that Works Consistently
- Continuing Process Improvement
Speaker
Gregory T. Bleck, Ph.D., Senior Director of Cell Line Engineering, Catalent Pharma Solutions
Dr. Bleck received his BS in Dairy Science and PhD in Endocrinology-Reproductive Physiology from the University of Wisconsin-Madison. He performed postdoctoral work at the University of Illinois-Urbana working in the areas of gene regulation and expression, and joined Catalent Pharma Solutions in 1998. At Catalent, Dr. Bleck transferred his knowledge of gene expression and transgenic systems to the development and continued optimization of retrovector expression systems and is one of the developers of the GPEx® technology. The GPEx® process is used at Catalent to develop high producing mammalian cell lines to be used for bio-manufacturing at the Middleton, WI facility. Dr. Bleck has published over 55 research papers and authored three book chapters. He is an inventor on eight issued patents and five patents currently under review.
Message PresenterWho Should Attend?
Characteristics of an Effective Mammalian Cell Line Generation Process for Bio-Pharmaceutical Production
Quickly and consistently generating stable, high productivity cell lines that produce protein of outstanding quality are the goals of any mammalian cell line process.
This talk will explore how steps in the generation of mammalian cell lines were optimized to make a process more efficient and outline certain risks that were taken to improve timelines and throughput.
Data collected from the development of over 200 cell lines, each producing a different antibody or recombinant protein will be summarized. An outline of our current CHO cell line development process that consistently yields clonal lines and upstream culture conditions that result in 2.5 – 5.0 g/L antibody production in five to six months will be presented.
Discussed topics will include:
- Optimizing the Gene Construct
- Minimizing Resources and Time During Clonal Selection
- Balancing Titer and Stability vs. Speed
- Addressing Protein Quality and Other Characteristics During the Process
- Finding a Quick Upstream Development Process that Works Consistently
- Continuing Process Improvement
Xtalks Partner
Catalent
Catalent maintains a continuum of services for biopharmaceutical development, including biosafety testing, bioassay development, preformulation and formulation development, stability studies and fill-finish capabilities.
For information about the recorded archive for this event contact Xtalks at (416) 977-6555 ext 371, or email [email protected]
Related Webinars
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account